Patents by Inventor Girish V. Shah

Girish V. Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
    Patent number: 9765115
    Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 19, 2017
    Assignee: Board of Supervisors of Louisiana State University acting on behalf of the University of Louisiana at Monroe
    Inventor: Girish V. Shah
  • Inhibitors of Metastasis, Methods of Generating Such Inhibitors and Their Therapeutic Applications
    Publication number: 20140286952
    Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 25, 2014
    Applicant: Board of Supervisors for the University of Louisia System, acting on behalf of the University of Lou
    Inventor: Girish V. Shah
  • Neuroendocrine marker of prostate cancer and method for producing same
    Patent number: 7026454
    Abstract: The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells and conjugates of NEM and a binding agent capable of inhibiting binding of NEM to its receptor.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: April 11, 2006
    Assignee: University of Kansas Medical Center
    Inventor: Girish V. Shah